Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Biological Effects of Radiation

Biological Effects of Radiation

All radioactive nuclides emit high-energy particles or electromagnetic waves. When this radiation encounters living cells, it can cause heating, break chemical bonds, or ionize molecules. The most serious biological damage results when these radioactive emissions fragment or ionize molecules. For example, α and β particles emitted from nuclear decay reactions possess much higher energies than ordinary chemical bond energies. When these particles strike and penetrate matter, they produce ions...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Mutations

Mutations

Mutations are changes in the sequence of DNA. These changes can occur spontaneously or they can be induced by exposure to environmental factors. Mutations can be characterized in a number of different ways: whether and how they alter the amino acid sequence of the protein, whether they occur over a small or large area of DNA, and whether they occur in somatic cells or germline cells.
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...

Mutagenicity and Carcinogenicity

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

ASCEND: a randomised, double-blinded, placebo-controlled, phase II study of gemcitabine and nab-paclitaxel with LSTA1 in untreated metastatic pancreatic adenocarcinoma. An Australasian Gastro-Intestinal Trials Group (AGITG) trial.

ESMO gastrointestinal oncology·2026

Same author

ESMO Guidance for Reporting Oncology real-World evidence (GROW).

ESMO real world data and digital oncology·2026

Same author

A Scoping Review of Human Teratogens and Their Impact on the Developing Brain: A Contribution From the ConcePTION Project.

Birth defects research·2025

Same author

Regional Lymph Node Delineation variability and its Dosimetric Impact in Breast Cancer Radiotherapy.

Clinical oncology (Royal College of Radiologists (Great Britain))·2025

Same author

Differential benefit of adjuvant everolimus according to endocrine therapy backbone in the randomized UNIRAD trial.

ESMO open·2025

Same author

Patient Experiences of Using Wearable Health Monitors During Cancer Treatment: A Qualitative Study.

Clinical oncology (Royal College of Radiologists (Great Britain))·2024

Search research articles

Related Experiment Video

Updated: Jul 20, 2026

Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines

Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines

Published on: August 21, 2019

Cellular radiosensitivity and complication risk after curative radiotherapy.

J Peacock¹, A Ashton, J Bliss

¹Section of Radiotherapy and Section of Epidemiology, Institute of Cancer Research, 15 Cotswold Road, Sutton, UK.

Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology

|May 9, 2000

Summary

This study found no link between fibroblast radiosensitivity and radiotherapy complications in breast cancer patients. Other factors likely explain variations in normal tissue damage after treatment.

More Related Videos

Live Imaging to Quantify Cellular Radiosensitivity in Patient-Derived Tumor Organoids

Live Imaging to Quantify Cellular Radiosensitivity in Patient-Derived Tumor Organoids

Published on: April 5, 2024

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes

Published on: May 23, 2025

Related Experiment Videos

Last Updated: Jul 20, 2026

Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines

Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines

Published on: August 21, 2019

Live Imaging to Quantify Cellular Radiosensitivity in Patient-Derived Tumor Organoids

Live Imaging to Quantify Cellular Radiosensitivity in Patient-Derived Tumor Organoids

Published on: April 5, 2024

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes

Published on: May 23, 2025

Area of Science:

Oncology
Radiation Oncology
Cell Biology

Background:

Radiotherapy dose fractionation is a standard treatment for breast cancer.
Late normal tissue effects can occur years after radiotherapy.
Inter-patient variability in these effects suggests underlying biological differences.

Purpose of the Study:

To investigate the association between in vitro fibroblast radiosensitivity and the risk of radiotherapy complications.
To determine if cellular radiosensitivity predicts normal tissue damage in breast cancer patients.

Main Methods:

A case-control study of breast cancer patients from a radiotherapy dose fractionation trial.
Fibroblast cell survival assays were performed at high and low dose rates.
Patients were selected based on the presence (cases) or absence (controls) of late normal tissue changes.

Main Results:

Significant inter-patient variation in fibroblast radiosensitivity was observed.
No association was found between fibroblast radiosensitivity and the development of late radiotherapy normal tissue effects.
This suggests cellular radiosensitivity is not a primary determinant of complication risk.

Conclusions:

Inter-individual variation in cellular radiosensitivity may not be the main factor determining radiotherapy complication risk in breast cancer.
Other biological and technical factors are likely more important in explaining differences in normal tissue damage.
Further research is needed to identify key determinants of radiotherapy-induced normal tissue injury.